Mark Elliott Boulding, who serves as Executive Vice President and Chief Legal Officer of PTC Therapeutics (NASDAQ: PTCT), completed a sequence of transactions on April 6, 2026 that included the sale of 2,265 shares of the company's common stock. The disposals generated proceeds of $157,293, with execution prices ranging from $68.91 to $69.75 per share. At the time of reporting, the stock was trading at $71.28, a figure that represents a 75% increase over the trailing 12 months.
In conjunction with the sale, Boulding exercised stock options to acquire 2,265 shares of PTC Therapeutics common stock at an exercise price of $39.42, for an aggregate exercise cost of $89,286. After these transactions, his direct holdings in the company stand at 105,212 shares.
The option exercised was originally granted on January 5, 2023 and is subject to a four-year vesting schedule. Under the terms disclosed, 25% of the underlying shares vested on January 5, 2024, with an additional 6.25% of the original grant vesting at the end of each subsequent three-month period beginning April 5, 2024. The sales were completed under a pre-arranged trading plan that Boulding adopted on September 10, 2025.
Recent company updates and analyst activity
PTC Therapeutics has been active on the corporate and regulatory fronts. The company reported fourth-quarter 2025 results after having pre-announced its 2025 revenues, and it provided fiscal 2026 guidance in January. Following those disclosures, several firms adjusted their outlooks. Morgan Stanley increased its price target for PTC Therapeutics to $92 and maintained an Overweight rating. Cantor Fitzgerald reiterated an Overweight rating with a $124 price target. Barclays initiated coverage with an Overweight rating and set a $119 price target, specifically noting the commercial potential for PTC's phenylketonuria treatment that could reach over $2 billion in peak sales.
On the regulatory side, PTC Therapeutics withdrew its New Drug Application resubmission for Translarna after receiving feedback from the U.S. Food and Drug Administration indicating that the submitted data might not satisfy approval standards. The company also expanded its board by appointing Jessica Chutter, who brings experience from Morgan Stanley.
Valuation insight referenced
Analysis cited in conjunction with the insider transaction suggests that the stock may be trading above its Fair Value on an InvestingPro assessment. That same source offers more detailed research products and reports on PTC Therapeutics for subscribers seeking additional context.
Contextual note
The disclosed insider activity - the concurrent option exercise and share sale executed through a pre-arranged plan - leaves Boulding with a material direct stake in the company while realizing proceeds from the sales. The company remains the subject of active analyst coverage and regulatory developments that have influenced recent market attention.
Summary of transactions
- Sale: 2,265 shares on April 6, 2026 for $157,293 at prices between $68.91 and $69.75.
- Option exercise: 2,265 shares at $39.42 for a total exercise cost of $89,286.
- Post-transaction direct ownership: 105,212 shares.
- Option grant date: January 5, 2023; vesting: 25% on January 5, 2024, plus 6.25% of original grant each quarter beginning April 5, 2024.
- Pre-arranged trading plan adoption date: September 10, 2025.